Metastatic Solid Tumors Clinical Trial
Official title:
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to other parts of the body.
This is a first-in-human study of DCC-2701. The primary purpose of this study is to determine
what dose of DCC-2701, can be given safely to patients with advanced solid tumors.
The study will have two phases. The first phase will assess escalating doses of DCC-2701 in
order to determine the maximally tolerated dose (MTD) and the optimal dosing regimen (ODR) of
DCC-2701. Once the MTD and ODR is established, a dose expansion phase will further evaluate
the safety of DCC-2701, as well as the activity of DCC-2701 in select solid tumor types.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03993873 -
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05494918 -
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
|
Phase 1 | |
| Completed |
NCT02281409 -
Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT01928459 -
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
|
Phase 1 | |
| Completed |
NCT01449370 -
Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT06031441 -
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03059823 -
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03573544 -
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03893955 -
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT00878423 -
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT00149019 -
Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.
|
Phase 2 | |
| Recruiting |
NCT03093116 -
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
|
Phase 1/Phase 2 | |
| Terminated |
NCT03854227 -
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04094610 -
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01543763 -
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05853367 -
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
|
Phase 1 | |
| Completed |
NCT02097810 -
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.
|
Phase 1 | |
| Recruiting |
NCT05836324 -
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03910530 -
A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT00148993 -
Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
|
Phase 1/Phase 2 |